| __timestamp | Regeneron Pharmaceuticals, Inc. | Viatris Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 504755000 | 1499100000 |
| Thursday, January 1, 2015 | 838526000 | 1923500000 |
| Friday, January 1, 2016 | 1177697000 | 2351400000 |
| Sunday, January 1, 2017 | 1320433000 | 2564000000 |
| Monday, January 1, 2018 | 1556200000 | 2397300000 |
| Tuesday, January 1, 2019 | 1834800000 | 2503400000 |
| Wednesday, January 1, 2020 | 1346000000 | 3344600000 |
| Friday, January 1, 2021 | 1824900000 | 4529200000 |
| Saturday, January 1, 2022 | 2115900000 | 4179100000 |
| Sunday, January 1, 2023 | 2631300000 | 4650100000 |
| Monday, January 1, 2024 | 2954400000 |
Data in motion
In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Regeneron Pharmaceuticals, Inc. and Viatris Inc. have shown distinct approaches to handling these costs. From 2014 to 2023, Regeneron has seen a steady increase in SG&A expenses, starting at approximately $505 million and peaking at $2.63 billion in 2023. This represents a more than fivefold increase, reflecting their aggressive expansion and investment in growth.
Conversely, Viatris Inc. has consistently maintained higher SG&A expenses, starting at $1.5 billion in 2014 and reaching $4.65 billion in 2023. Despite this, their expenses have grown at a slower rate compared to Regeneron, indicating a more stable cost management strategy. As investors and analysts evaluate these companies, understanding their SG&A trends provides valuable insights into their operational efficiency and strategic priorities.
Breaking Down SG&A Expenses: Zoetis Inc. vs Viatris Inc.
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Biogen Inc.
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Dr. Reddy's Laboratories Limited
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Ultragenyx Pharmaceutical Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc. Trends and Insights
Regeneron Pharmaceuticals, Inc. and Vericel Corporation: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Evotec SE
SG&A Efficiency Analysis: Comparing Viatris Inc. and BioMarin Pharmaceutical Inc.
Selling, General, and Administrative Costs: Viatris Inc. vs Ultragenyx Pharmaceutical Inc.
Operational Costs Compared: SG&A Analysis of Viatris Inc. and Corcept Therapeutics Incorporated
Cost Management Insights: SG&A Expenses for Viatris Inc. and BioCryst Pharmaceuticals, Inc.